Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis

• Published in: Lupus 2018-04, Vol.27 (4), p.572-583
• Main Authors: Abdel-Wahab, N, Talathi, S, Lopez-Olivo, M A, Suarez-Almazor, M E
• Format: Article
• Language: English
• Subjects: Antibodies, Antiphospholipid - blood; Antiphospholipid antibodies; Antiphospholipid Syndrome - blood; Antiphospholipid Syndrome - diagnosis; Antiphospholipid Syndrome - epidemiology; Antiphospholipid Syndrome - immunology; Autoimmune diseases; Biomarkers - blood; Cardiolipin; Clinical trials; Epstein-Barr virus; Female; Glycoprotein I; Health risk assessment; Hepatitis; Hepatitis B; Hepatitis C; HIV; Host-Pathogen Interactions; Human immunodeficiency virus; Humans; Immunoglobulins; Infections; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - epidemiology; Lupus Erythematosus, Systemic - immunology; Meta-analysis; Observational studies; Odds Ratio; Parvoviruses; Pregnancy; Pregnancy Complications, Cardiovascular - blood; Pregnancy Complications, Cardiovascular - diagnosis; Pregnancy Complications, Cardiovascular - epidemiology; Pregnancy Complications, Cardiovascular - immunology; Prevalence; Risk Assessment; Risk Factors; Statistical analysis; Systematic review; Thromboembolism; Thromboembolism - blood; Thromboembolism - diagnosis; Thromboembolism - epidemiology; Thromboembolism - immunology; Viral infections; Virus Diseases - diagnosis; Virus Diseases - epidemiology; Virus Diseases - virology
• ISSN: 0961-2033; 1477-0962
• DOI: 10.1177/0961203317731532

Objective The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection. Method We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included. Results We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6–19.4), as were those with HCV (RR 6.3, 95% CI 3.9–10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8–9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4–22.2). The only statistically significant increased risk for anti-β2-glycoprotein I (anti-β2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0–22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3–2.6), and those with EBV, elevated anti-β2-GPI antibodies (RR 2.2, 95% CI 1.3–3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0–18.1), and HBV (5.9%, 95% CI 2.0–11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78–45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL. Conclusions Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information.